Every material Form 8-K RIGEL PHARMACEUTICALS INC has filed with the SEC since July 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Rigel reported third quarter 2026 total revenues of $80.9 million, up from $69.5 million a year earlier, driven by net product sales of $72.3 million, including $6.6 million from newly launched VEPPANU. Net income fell to $13.2 million, or $0.65 per diluted share, from $27.9 million, or $1.46 per diluted share, as costs and expenses rose to $63.8 million from $41.0 million. The company raised its 2026 total revenue guidance at the low end, to $290 to $295 million, but lowered its net product sales range to $255 to $260 million.
Q3 2026 total revenues $80.9 million vs. $69.5 million in Q3 2025; net product sales up 13%
Q3 2026 net income $13.2 million ($0.65 diluted per share) vs. $27.9 million ($1.46) a year earlier
2026 total revenue guidance raised to $290 to $295 million from $285 to $295 million; net product sales guidance lowered to $255 to $260 million from $255 to $265 million
VEPPANU became commercially available August 13, 2026; cash and short-term investments were $99.3 million at September 30, 2026
Rigel reported second quarter 2026 total revenues of $78.7 million, down from $101.7 million a year earlier, which included $40.0 million in non-cash collaboration revenue. Net income was $17.3 million, or $0.88 per diluted share, versus $59.6 million, or $3.28 per diluted share, in the prior year period. The company raised its 2026 total revenue outlook to $285 million to $295 million, excluding VEPPANU, which it in-licensed in June and expects to launch in mid-August.
Net product sales rose 14% to $67.0 million; TAVALISSE $47.4 million (up 18%), REZLIDHIA $8.9 million (up 27%), GAVRETO $10.7 million (down 10%).
Total revenues were $78.7 million versus $101.7 million; the prior year included $40.0 million in non-cash revenue tied to Eli Lilly.
2026 total revenue guidance raised to $285 million to $295 million from $275 million to $290 million.
Rigel paid a $70.0 million upfront payment for VEPPANU; cash and short-term investments were $95.3 million at June 30, 2026, versus $155.0 million at December 31, 2025.
Rigel Pharmaceuticals appointed director Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer effective July 1, 2026, and she resigned from the Board at the same time. The filing also says Lisa Rojkjaer, M.D. left the Chief Medical Officer role and the company effective June 25, 2026, so the change is a leadership transition in a key clinical position.
Alison L. Hannah, M.D. appointed Executive Vice President and Chief Medical Officer on July 1, 2026
Dr. Hannah resigned from the Board of Directors effective July 1, 2026; she had served on the Board since May 2021
Lisa Rojkjaer, M.D. ceased to be Executive Vice President and Chief Medical Officer and separated from the company effective June 25, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every RIGEL PHARMACEUTICALS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →